RT Journal Article SR Electronic T1 GWAS meta-analysis and gene expression data link reproductive tract development, immune response and cellular proliferation/apoptosis with cervical cancer and clarify overlap with other cervical phenotypes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.18.21259075 DO 10.1101/2021.06.18.21259075 A1 Mariann Koel A1 Urmo Võsa A1 Maarja Lepamets A1 Hannele Laivuori A1 Susanna Lemmelä A1 Mark Daly A1 Estonian Biobank Research Team A1 FinnGen A1 Priit Palta A1 Reedik Mägi A1 Triin Laisk YR 2021 UL http://medrxiv.org/content/early/2021/06/27/2021.06.18.21259075.abstract AB Background The uterine cervix has an important role in female reproductive health, but not much is known about the genetic determinants of cervical biology and pathology. Genome-wide association studies (GWAS) with increasing sample sizes have reported preliminary genetic associations for cervical cancer. However, GWAS is only the first step in mapping the genetic susceptibility and thus, the underlying biology in cervical cancer and other cervical phenotypes is still not entirely understood. Here, we use data from large biobanks to characterise the genetics of cervical phenotypes (including cervical cancer) and leverage latest computational methods and gene expression data to refine the association signals for cervical cancer.Methods Using Estonian Biobank and FinnGen data, we characterise the genetic signals associated with cervical ectropion (10,162 cases/151,347 controls), cervicitis (19,285/185,708) and cervical dysplasia (14,694/150,563). We present the results from the largest trans-ethnic GWAS meta-analysis of cervical cancer, including up to 9,229 cases and 490,304 controls from Estonian Biobank, the FinnGen study, the UK Biobank and Biobank Japan. We combine GWAS results with gene expression data and chromatin regulatory annotations in HeLa cervical carcinoma cells to propose the most likely candidate genes and causal variants for every locus associated with cervical cancer. We further dissect the HLA association with cervical pathology using imputed data on alleles and amino acid polymorphisms.Results We report a single associated locus on 2q13 for both cervical ectropion (rs3748916, p=5.1 × 10−16) and cervicitis (rs1049137, p=3.9 × 10−10), and five signals for cervical dysplasia - HLA-B and HLA-DQA1 (rs1053726, p=9.1 × 10−9; rs36214159, 1.6 × 10−22), DAPL1 (rs12611652, p=3.2 × 10−9), PAX8 (rs1049137, p=6.4 × 10−9), and CLPTM1L (rs6866294, p=2.1 × 10−9). We identify five loci associated with cervical cancer in the trans-ethnic meta-analysis: LINC00339/CDC42 (rs2268177, p= 3.1 × 10−8), PAX8/PAX8-AS1 (rs4849177, p=9.4 × 10−15), CLPTM1L (rs27069, p=1.3 × 10−14), GSDMB (rs12603332, p=1.2 × 10−9), and HLA-DRB1/HLA-DQA1 (rs35508382, p=1.0 × 10−39). Joint analysis of dysplasia and cancer datasets revealed an association on chromosome 19 (rs425787, p=3.5 × 10−8), near CD70.Discussion Our results map PAX8/PAX8-AS1, LINC00339, CDC42, CLPTM1L, HLA-DRB1, HLA-B, and GSDMB as the most likely candidate genes for cervical cancer, which provides novel insight into cervical cancer pathogenesis and supports the role of genes involved in reproductive tract development, immune response, and cellular proliferation/apoptosis. We further show that PAX8/PAX8-AS1 has a central role in cervical biology and pathology, as it was associated with all analysed phenotypes. The detailed characterisation of association signals, together with mapping of causal variants and genes offers valuable leads for further functional studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by European Union through Horizon 2020 grant INTERVENE, and by the Estonian Research Council grants PRG687 and PRG1291. Computations were performed in the High Performance Computing Center, University of Tartu. U.V was funded by the European Regional Development Fund and the programme Mobilitas Pluss (MOBTP108). The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, and Novartis AG. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All Estonian biobank participants have signed a broad informed consent form and the study was carried out under ethical approval 1.1-12/624 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs). Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFinnGen R5 data can be browsed and downloaded from https://r5.finngen.fi. Biobank Japan data can be browsed and downloaded from http://jenger.riken.jp:8080. GWAS meta-analysis summary statistics will be made available upon publication of this manuscript. https://r5.finngen.fi. http://jenger.riken.jp:8080